The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February and going through at least mid-2025.

(Bloomberg) -- Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year ...

Biopharma giant MSD says it stands ready to pursue new approaches to advance public health in China after its GARDASIL ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare ...

The message was apparently designed to fit a broader push in China to boost male vaccination against HPV-related diseases following Gardasil’s local approval earlier this year in males aged 9 to 26.

Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China remain overhangs. There are concerns about Merck’s ability ...

MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.